The role and efficacy of denosumab in the treatment of osteoporosis: an update.

Abstract:

INTRODUCTION:Bone strength determinants such as bone mineral density and bone quality parameters are determined by life-long remodeling of skeletal tissue. Denosumab is a fully human mAb receptor activator of NF-κB ligand, which selectively inhibits osteoclastogenesis, the end product of a cascade interaction among numerous systemic and local factors and osteoblasts. It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(™), Amgen, Thousand Oaks, CA, USA). AREAS COVERED:This review establishes the concerns and provides insights in issues concerning the cost-effectiveness and safety profile of this new pharmaceutical agent. There is an effort to clarify the special characteristics and the anti-catabolic role of denosumab in the bone tissue homeostasis and more specifically its potential clinical applications and clinical results in the field of postmenopausal osteoporosis. EXPERT OPINION:Administrated as a subcutaneous injection every 6 months, denosumab has been shown to decrease bone turnover and increase bone mineral density in postmenopausal women with low bone mass or osteoporosis and reduce vertebral, hip and nonvertebral fracture risk in postmenopausal women with osteoporosis. The rapid, sustained and reversible effect in suppressing osteoclastic bone resorption, the return of responsiveness on rechallenge, its good tolerability and ease of administration are features that distinguish it from other antiresorptive therapies.

journal_name

Expert Opin Drug Saf

authors

Charopoulos I,Orme S,Giannoudis PV

doi

10.1517/14740338.2010.516249

subject

Has Abstract

pub_date

2011-03-01 00:00:00

pages

205-17

issue

2

eissn

1474-0338

issn

1744-764X

journal_volume

10

pub_type

杂志文章,评审
  • Risks and benefits of pre-operative dexmedetomidine in oral and maxillofacial surgeries: a systematic review.

    abstract:INTRODUCTION:Oral and maxillofacial surgeries might induce anxiety and pain to the patients. Sedative agents are one of the best ways for eliminating such consequences. Dexmedetomidine (DEX) is a recent sedative agent which presents higher sedative quality with greater specificity than other drugs. The aim of present p...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1323865

    authors: Davoudi A,Movahedian Attar B,Shadmehr E

    更新日期:2017-06-01 00:00:00

  • The safety of available treatments options for neuroendocrine tumors.

    abstract:INTRODUCTION:Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to sum...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1354984

    authors: Faggiano A,Lo Calzo F,Pizza G,Modica R,Colao A

    更新日期:2017-10-01 00:00:00

  • A safety evaluation of guselkumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of Th-17-derived pro-inflammatory cytokines, especially IL-17 and IL-22. Areas covered: ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1488963

    authors: Galluzzo M,D'Adamio S,Campione E,Bianchi L,Talamonti M

    更新日期:2018-07-01 00:00:00

  • Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?

    abstract:INTRODUCTION:Over the past decade, increased prescription supply has facilitated an epidemic of nonmedical use of controlled substances, including predominantly opioids, as well as benzodiazepines, z-hypnotics, and stimulants. Areas covered: More recently, misuse of noncontrolled prescriptions, such as gabapentin, has ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2017.1390081

    authors: Peckham AM,Fairman KA,Sclar DA

    更新日期:2018-05-01 00:00:00

  • CGRP inhibitors for migraine prophylaxis: a safety review.

    abstract:INTRODUCTION:Since calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine via the activation of the trigeminovascular system, the newest prophylactic treatments directly block CGRP or its receptor. However, the safety of these novel antimigraine drugs is not yet sufficiently e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1811229

    authors: Rivera-Mancilla E,Villalón CM,MaassenVanDenBrink A

    更新日期:2020-10-01 00:00:00

  • Safety of ACE inhibitor therapies in patients with chronic kidney disease.

    abstract:INTRODUCTION:ACE inhibitors are first-line therapy in patients with chronic kidney disease (CKD). The main adverse effects of ACE inhibitors are hypotension, renal function impairment and hyperkalemia. AREAS COVERED:This paper reviews evidence from clinical studies regarding adverse effects of ACE inhibitors in patien...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.951328

    authors: Sidorenkov G,Navis G

    更新日期:2014-10-01 00:00:00

  • An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.

    abstract:INTRODUCTION:Oral antidiabetic medications are important in many type 2 diabetes care plans. AREAS COVERED:The article summarizes the cardiovascular and renal safety data for DPP-4 inhibitors and SGLT-2 inhibitors and specific safety data particular to each class. EXPERT OPINION:DPP-4 and SGLT-2 inhibitors provide un...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1626823

    authors: Lamos EM,Hedrington M,Davis SN

    更新日期:2019-08-01 00:00:00

  • Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management.

    abstract:INTRODUCTION:The number of HIV patients receiving antiretroviral therapy is increasing worldwide, as new infections continue to occur and access to drugs is scaling up in most developing regions. Due to the efficacious nature of combination antiretroviral therapy in most drug-adherent patients, the concerns on the safe...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.806480

    authors: Fernandez-Montero JV,Eugenia E,Barreiro P,Labarga P,Soriano V

    更新日期:2013-09-01 00:00:00

  • The safety of pharmacological treatment options for lupus nephritis.

    abstract:INTRODUCTION:The management of lupus nephritis (LN) has changed significantly over the last 10 years due to emerging evidence from large randomised clinical trials that produced good quality data and guided the formulation of two key concepts: the induction of remission and the maintenance phase of immunosuppressive th...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1182496

    authors: Velo-García A,Ntatsaki E,Isenberg D

    更新日期:2016-08-01 00:00:00

  • Efficacy and safety of mipomersen sodium (Kynamro).

    abstract:INTRODUCTION:Mipomersen is a first-in-class drug indicated as an adjunct to lipid-lowering medications and diet to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholes...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.793670

    authors: Hovingh K,Besseling J,Kastelein J

    更新日期:2013-07-01 00:00:00

  • Neuropsychiatric side effects of efavirenz therapy.

    abstract::The non-nucleoside analogue inhibitor of the reverse transcriptase, efavirenz (EFV), has become commonly used in highly active antiretroviral combination therapy in the treatment of HIV infection. Although being effective in suppressing plasma viral load, neuropsychiatric side effects have been reported in individuals...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.6.2.147

    authors: Arendt G,de Nocker D,von Giesen HJ,Nolting T

    更新日期:2007-03-01 00:00:00

  • Atorvastatin: safety and tolerability.

    abstract:IMPORTANCE OF THE FIELD:Atorvastatin is the most widely used statin administered in a variety of settings, including primary and secondary prevention of cardiovascular events, in the elderly, in patients with chronic kidney disease and in diabetic patients. Therefore, the safety and tolerability of atorvastatin is of p...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2010.495385

    authors: Athyros VG,Tziomalos K,Karagiannis A,Mikhailidis DP

    更新日期:2010-07-01 00:00:00

  • The safety and tolerability of the second-line injectable antituberculosis drugs in children.

    abstract:INTRODUCTION:A growing number of children globally are being treated for multidrug-resistant tuberculosis (MDR-TB). The second-line injectable antituberculosis medications amikacin, kanamycin and capreomycin, traditionally a mainstay of MDR-TB treatment, cause important adverse effects including permanent sensorineural...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1223623

    authors: Garcia-Prats AJ,Schaaf HS,Hesseling AC

    更新日期:2016-11-01 00:00:00

  • Adrenaline in anaphylaxis treatment. Balancing benefits and harms.

    abstract:INTRODUCTION:Although anaphylaxis is a relatively common disorder, clinicians and scientists have debated on how to best define and manage this condition. The current recommendations are focused on the central role of adrenaline, but evidence in support of this therapeutic approach is modest, mainly for the lack of wel...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2016.1167870

    authors: Cervellin G,Sanchis-Gomar F,Lippi G

    更新日期:2016-06-01 00:00:00

  • Monitoring self-medication.

    abstract::Self-medication, using non-prescription drugs, is beneficial to patients, healthcare professionals, the pharmaceutical industry and governments. Although many non-prescription medications are effective, misuse and abuse of these products can arise. Monitoring of specific populations and products, in addition to data r...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.2.1.1

    authors: Hughes CM

    更新日期:2003-01-01 00:00:00

  • Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding.

    abstract::Aspirin use is associated with gastroduodenal mucosal damage and increased risk of upper gastrointestinal (GI) bleeding. Many aspirin users should receive prophylactic treatment since they often have several risk factors for upper GI complications. The best therapeutic approach for reducing GI toxicity in low-dose asp...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.1.3.245

    authors: Lanas A,Ferrández A

    更新日期:2002-09-01 00:00:00

  • Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.

    abstract:INTRODUCTION:Atrial fibrillation (AF) is a cause of significant morbidity and mortality. Catheter ablation for AF (CAAF) has emerged as an effective treatment option of rhythm control for patients with symptomatic AF. However, the risk of thromboembolism and bleeding in the periprocedural period represent a worrisome c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1325867

    authors: Briceño DF,Madan N,Romero J,Londoño A,Villablanca PA,Natale A,Di Biase L

    更新日期:2017-07-01 00:00:00

  • Methotrexate pulmonary toxicity.

    abstract::Methotrexate is a commonly prescribed antineoplastic and immune modulating compound that has gained wide acceptance in the management of rheumatoid arthritis, psoriasis, sarcoidosis and a number of neoplastic disorders. Although generally considered safe and easy to use, methotrexate has been associated with a number ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.4.723

    authors: Lateef O,Shakoor N,Balk RA

    更新日期:2005-07-01 00:00:00

  • Safety considerations when using drugs to treat pruritus.

    abstract::Introduction: Treatment for chronic pruritus ranges from use of topical formulations to newer biologic agents. Targeting treatment to the underlying etiology is key in reducing the burden of disease while avoiding systemic or adverse effects.Areas covered: This review details the effective medical treatments used in v...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1728252

    authors: Fourzali K,Yosipovitch G

    更新日期:2020-04-01 00:00:00

  • Safety of anticholinergics in patients with benign prostatic hyperplasia.

    abstract:BACKGROUND:Storage lower urinary tract symptoms (LUTS) or overactive bladder (OAB) often coexist with voiding symptoms in patients with benign prostatic obstruction (BPO). Anticholinergic medications to treat storage LUTS are often withheld in such patients for fear of significantly increasing post-void residual urine ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.7.4.473

    authors: Athanasopoulos A,Mitropoulos D,Giannitsas K,Perimenis P

    更新日期:2008-07-01 00:00:00

  • A safety evaluation of evolocumab.

    abstract:INTRODUCTION:Evolocumab is an injectable, fully human monoclonal antibody and a member of the newest class of low density lipoprotein cholesterol (LDL-C) lowering agents called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The PCSK9 inhibitors are the most significant advance in lipid therapy since ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2018.1389892

    authors: Roth EM

    更新日期:2018-01-01 00:00:00

  • Cardiovascular effects of anti-diabetes drugs.

    abstract:INTRODUCTION:Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1195368

    authors: Younk LM,Lamos EM,Davis SN

    更新日期:2016-09-01 00:00:00

  • Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance.

    abstract::Objectives: Sensory adverse drug reactions (ADRs) are generally expected to be transient in nature. However, spontaneous reports describe frequently these events as long-lasting or unresolved. In this study, the authors reviewed the Eudravigilance publicly accessible database to describe the volume and expectedness of...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1676724

    authors: Ferraro S,Convertino I,Leonardi L,Blandizzi C,Tuccori M

    更新日期:2019-12-01 00:00:00

  • A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.

    abstract::Introduction: Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states' varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relativ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1643837

    authors: Afifi S,Mohamed S,Zhao J,Foss F

    更新日期:2019-09-01 00:00:00

  • Evaluation of dolutegravir safety for the treatment of HIV-1.

    abstract:INTRODUCTION:Dolutegravir (DGV) is the newest integrase inhibitor approved for the treatment of HIV-1 infection in both treatment-naive and experienced adults and adolescents. This article reviews the safety of DGV for the treatment of HIV-1 infection. AREAS COVERED:The PubMed database was searched using the keywords ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2015.973845

    authors: Keeshin SW,Feinberg J

    更新日期:2015-01-01 00:00:00

  • Application of botulinum toxin in pregnancy and its impact on female reproductive health.

    abstract::Introduction: Botulinum toxin (BoNT) is a protein secreted by the anaerobic Gram-negative bacterium Clostridium botulinum. Among the seven known subtypes, type A is the most commonly used in women to treat diseases. It primarily blocks presynaptic release of acetylcholine at the neuromuscular junction, resulting in te...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1707803

    authors: Li W,Tang M

    更新日期:2020-01-01 00:00:00

  • Statin use and the risk of kidney cancer: a population-based case-control study.

    abstract:OBJECTIVE:To investigate whether the use of statins was associated with kidney cancer risk. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older, and had a first-time diagnosis of kidney cancer for the period between 2005 and 2009. The c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2012.678831

    authors: Chiu HF,Kuo CC,Kuo HW,Lee IM,Lee CT,Yang CY

    更新日期:2012-07-01 00:00:00

  • Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

    abstract:IMPORTANCE OF THE FIELD:Despite the beneficial effect of imatinib treatment in chronic myeloid leukemia patients, some patients develop resistance and/or intolerance and need a switch to second-generation tyrosine kinase inhibitors. Dasatinib is indicated for chronic myeloid leukemia patients with resistance or intoler...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740331003742935

    authors: Breccia M,Alimena G

    更新日期:2010-09-01 00:00:00

  • Drug-induced parkinsonism.

    abstract:INTRODUCTION:Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after idiopathic Parkinson's disease (iPD). Initially reported as a complication of antipsychotics, it was later recognized as a common complication of antidepressants, calcium channel antagonists, gastrointestinal prokinetics,...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.787065

    authors: López-Sendón J,Mena MA,de Yébenes JG

    更新日期:2013-07-01 00:00:00

  • Application of bone morphogenetic proteins in orthopaedic practice: their efficacy and side effects.

    abstract::Bone morphogenetic proteins (BMPs) have been extensively studied since the discovery of agents within bone that could induce bone formation at ectopic sites by Urist in the 1960s. Extensive preclinical research has been carried out showing the efficacy of these products in promoting bone healing. Clinical trials are e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.1.75

    authors: Harwood PJ,Giannoudis PV

    更新日期:2005-01-01 00:00:00